Ablynx receives €5m milestone payment from Boehringer
Boehringer Ingelheim has selected a second Nanobody candidate for pre-clinical development, which resulted in a €5m milestone payment to Ablynx.
The Nanobody development candidate is designed to interfere with the function of two distinct proteins that are thought to play a major role in human cancers.
To date, Ablynx has earned more than €57m in cash from the strategic alliance with Boehringer on the discovery, development and commercialisation of Nanobody therapeutics.
Ablynx CEO and chairman Edwin Moses said Boehringer has three Nanobody candidates in pre-clinical development including a Nanobody relevant in Alzheimer's disease.
"We anticipate additional Nanobodies will be advanced into formal development during the next years," Moses added.
Related Insight
Suppliers Directory
Phage Consultants - Contamination Prevention Services
Contaminations are one of major threats in bioprocesses. If contamination occurs, it may result in complete paralysis of facility productivity. Although even the best protection do not guarantee they never occur, better prepared facility will recover faster, and the contamination will not turn into outbreak. The company Phage Consultants was created to help companies which production is based on microbial activities, to fight with and prevent from bacteriophages and other contaminants. Based on our research and experience we propose different ways of assistance: from personnel training, through consulting and process optimization, to help in development of new facilities. Phage Consultants can help you in avoiding contaminations and in recovery from contaminations, which already occurred.
Contract Research & Services > Contract Research > Suppliers
GC-2 - Central Laboratory Solutions for Pharmaceutical Research and Development
Precise, continually updated information is an essential element of the efficiency of the best products and services.
Contract Research & Services > Contract Research > Suppliers
ikfe CRO - Diabetes and Cardiovascular Research
ikfe CRO, the experts for diabetes and cardiovascular research, provide a wide range of services to pharmaceutical and biotechnology companies across the world.
Contract Research & Services > Contract Research > Suppliers
Aptuit - Drug Discovery and Development
Aptuit is a pharmaceutical service company conducting research, development and manufacturing on a contract basis for large and small innovators.
Contract Research & Services > Contract Research > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
What is ZeoCool?
Published by SCA Cool Logistics
Contract Research & Services > Contract Research > White Papers
Outsourcing Best Practices
Published by Medpace
Contract Research & Services > Contract Research > White Papers
Right Place, Right Time
Published by Centrical Global Limited
Contract Research & Services > Contract Research > White Papers
Improving Clinical Site Productivity
Published by Kinapse
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.